BSE filing, NSE: JUBLINGREA. Summary written from the filing by ALFA Finder's alert engine.
Jubilant Ingrevia Ltd: key numbers
- Share price
- ₹593.60
- Market cap
- ₹9,455 Cr
- Revenue (annual)
- ₹4,388 Cr
- Net profit (annual)
- ₹277.9 Cr
- P/E (TTM)
- 27.0×Sector 34.1×
- Promoter holding
- 45.22%+0.00% QoQ
- FII holding
- 6.93%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Jubilant Ingrevia Ltd
All →Jubilant Ingrevia Earnings Call Transcript: Key Takeaways
Strong Q2 performance driven by volume growth across specialty chemicals and nutrition despite price softness in China.
Jubilant Ingrevia Management Change
Jubilant Ingrevia's Sr. Vice President & Head HR, Ms. Vinita Koul, resigned effective November 6, 2026. The departure is to pursue other interests.
Jubilant Ingrevia Investor Presentation: Key Takeaways
Q2 FY27 revenue ₹1,394 Cr (+24% YoY), EBITDA ₹221 Cr (+51%, 16% margin), PAT ₹111 Cr (+61%). Pinnacle strategy continues; 40% ZettaOne stake (₹189.2 Cr) enters EDMS.
Jubilant Ingrevia Q2 FY27 Results: Net Profit ₹111.4 Cr, Up 60.3% YoY
Jubilant Ingrevia Ltd reported revenue from operations of ₹1,394 Cr (+24.4% YoY) and net profit of ₹111.4 Cr (+60.3% YoY) for Q2 FY27.
- Key figure
- Net profit ₹111.4 Cr · +60.3% YoY
Jubilant Ingrevia Other Announcement
This is the quarterly shareholding pattern filing for Jubilant Ingrevia Ltd for the period ending September 30, 2026. It is a routine regulatory submission.
Jubilant Ingrevia Board Meeting Date
Jubilant Ingrevia Limited has scheduled a board meeting for October 27, 2026, to consider the unaudited standalone and consolidated financial results for the quarter.
Other employee stock options announcements
All →RateGain Travel Technologies Employee Stock Options
RateGain granted 53,021 Stock Appreciation Rights under its SAR Scheme 2022 at ₹800 and ₹862.25 per unit. The grants vest over four years and are exercisable within three years of vesting.
- Execution
- Vesting over 4 years (10% Y1, 20% Y2, 30% Y3, 40% Y4); exercisable within 3 years of vesting
Aye Finance Employee Stock Options
Aye Finance's employee welfare trust transferred 89,501 equity shares to grantees on exercising ESOP options. The share capital remains unchanged, so no new issuance occurs.
Aarti Pharmalabs Employee Stock Options
Aarti Pharmalabs granted 850 stock options to employees under its PSOP 2023 at Rs.5 exercise price. This is an employee incentive grant, not a capital raise.
OnEMI Technology Solutions Employee Stock Options
OnEMI Technology allotted 69,000 equity shares on exercise of employee stock options under the Kissht ESOP 2022 plan. The shares rank pari passu with existing equity.
Bliss GVS Pharma Employee Stock Options
Bliss GVS Pharma seeks shareholder approval via postal ballot for new employee stock option plans 2026. Up to 26,50,000 options are proposed; voting closes November 27, 2026.
Bandhan Bank Employee Stock Options
Bandhan Bank's board granted 32,98,871 stock options under ESOP Series 1 (Tranche 9) at Rs 151.91 per option. The options vest over four years, with each option convertible into one equity share.